VivoSeq
0

Pipeline Programs

5

Active Trials

3

Companies Involved

Varicella is an early-stage landscape with 0 programs across 3 companies. The most active players are GSK, Merck & Co., Sanofi.

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

19/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

16

clinical trials

Completed6 · 38%
Withdrawn3 · 19%
Not yet recruiting2 · 13%
Unknown status2 · 13%
Enrolling by invitation2 · 13%
Recruiting1 · 6%

Trial Activity

16 trials

Safety of a Second Dose of Biken's Varicella Vaccine
Completed·Sanofi logoSanofi·Phase 4·NCT00830648·122 enrolled
Study of Two Formulations of GSK Biologicals' Varicella Vaccine
Completed·GSK logoGSK·Phase 2·NCT00568334·244 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)